MiMedx Group, Inc. is a pharmaceutical company based in the United States that specializes in developing and marketing regenerative biomaterial products and bioimplants derived from human tissues. Their products, including EpiFix and AmnioFix, are used in wound-care, burn treatment, surgical procedures, sports medicine, and orthopedics. MiMedx also offers products for ophthalmic surgery and dental applications through licensing agreements. With an ESG score of 27.5, the company is assessed as having a medium risk profile.